# US 2021/0198246 A1 · Apelin receptor agonists and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0198246 A1
- Document ID: US20210198246A1
- Status: Published application
- Kind: A1
- Application number: 15/779,194
- Filed: 2016-12-02
- Published: 2021-07-01
- Earliest claimed: 2015-12-04
- Assignees: Bristol-Myers Squibb Company
- Applicants: Bristol-Myers Squibb Company
- Inventors: Wei Meng; Hannguang J. Chao; Heather Finlay; R. Michael Lawrence; Michael C. Myers
- Web page: https://patentgrep.com/patent/US20210198246A1

## CPC

- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 413/10: linked by a carbon chain containing aromatic rings
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 239/54: as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D 401/10: linked by a carbon chain containing aromatic rings
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 403/10: linked by a carbon chain containing aromatic rings
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 417/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 417/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.

## Claims

### Claim 1

A compound of Formula (I):
or a stereoisomer, an enantiomer, a diastereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:
alk is C1-6 alkyl substituted with 1-5 R4;
ring A is independently selected from 5- or 6-membered aryl and heteroaryl comprising carbon atoms and 1-4 heteroatoms selected from N, NR3a, O, and S, each substituted with 1-3 R3 ring B is independently selected from aryl, heteroaryl, and cycloalkyl, each substituted with 1-4 R1;
R1 is independently selected from H, halogen, NO2, —(CH2)nORb, (CH2)nS(O)pRc, —(CH2)nC(═O)Rb, —(CH2)nNRaRa, —(CH2)nCN, —(CH2)nC(═O)NRaRa, —(CH2)nNRaC(═O)Rb, —(CH2)nNRaC(═O)NRaRa, —(CH2)nNRaC(═O)ORb, —(CH2)nOC(═O)NRaRa, —(CH2)nC(═O)ORb, —(CH2)nS(O)pNRaRa, —(CH2)nNRaS(O)pNRaRa, —(CH2)nNRaS(O)pRc, C1-4 alkyl substituted with 0-3 Re, —(CH2)n—C3-6 carbocyclyl substituted with 0-3 Re, and —(CH2)n-heterocyclyl substituted with 0-3 Re;
R2 is independently selected from C2-5 alkyl substituted with 0-3 Re; C2-5 alkenyl substituted with 0-3 Re, aryl substituted with 1-3 Re, heterocyclyl substituted with 0-3 Re, and C3-6 cycloalkyl substituted with 0-3 Re; provided when R2 is C2-5 alkyl, the carbon atom and the groups attached thereto except the one attached to the pyrimidine ring may be replaced by O, N, and S;
R3 is independently selected from H, halogen, —(CH2)nORb, —(CH2)nS(O)pRc, —(CH2)nC(═O)Rb, —(CH2)nNRaRa, —(CH2)nCN, —(CH2)nC(═O)NRaRa, —(CH2)nNRaC(═O)Rb, —(CH2)nNRaC(═O)NRaRa, —(CH2)nNRaC(═O)ORb, —(CH2)nOC(═O)NRaRa, —(CH2)nC(═O)ORb, —(CH2)nS(O)pNRaRa, —(CH2)nNRaS(O)pNRaRa, —(CH2)nNRaS(O)pRc, C1-5 alkyl substituted with 0-3 Re, (CH2)n—C3-6 carbocyclyl substituted with 0-3 Re, and —(CH2)n-heterocyclyl comprising carbon atoms and 1-4 heteroatoms selected from N, NR3a, O, S, and substituted with 0-3 Re;
R3a is independently selected from H, —S(O)pRc, —C(═O)Rb, —C(═O)NRaRa, —C(═O)ORb, —S(O)pNRaRa, C1-5 alkyl substituted with 0-3 Re, —(CH2)n—C3-6 carbocyclyl substituted with 0-3 Re, and —(CH2)n-heterocyclyl substituted with 0-3 Re;
R4 is independently selected from C1-5 alkyl substituted with 0-3 Re, (CH2)n—C3-6 carbocyclyl substituted with 0-3 Re, and —(CH2)n-heterocyclyl substituted with 0-3 Re;
Ra, at each occurrence, is independently selected from H, C1-6 alkyl substituted with 0-5 Re, C2-6 alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re, —(CH2)n—C3-10carbocyclyl substituted with 0-5 Re, and —(CH2)n-heterocyclyl substituted with 0-5 Re; or Ra and Ra together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 Re;
Rb, at each occurrence, is independently selected from H, C1-6 alkyl substituted with 0-5 Re, C2-6 alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re, —(CH2)n—C3-10carbocyclyl substituted with 0-5 Re, and —(CH2)n-heterocyclyl substituted with 0-5 Re;
Rc, at each occurrence, is independently selected from C1-6 alkyl substituted with 0-5 Re, C2-6alkenyl substituted with 0-5 Re, C2-6alkynyl substituted with 0-5 Re, C3-6carbocyclyl, and heterocyclyl;
Rd, at each occurrence, is independently selected from H and C1-6 alkyl substituted with 0-5 Re;
Re, at each occurrence, is independently selected from C1-6 alkyl (optionally substituted with halogen, OH, and CN), C2-6 alkenyl, C2-6 alkynyl, —(CH2)n—C3-6 cycloalkyl, —(CH2)n—C4-6 heterocyclyl, —(CH2)n-aryl, —(CH2)n-heteroaryl, F, Cl, Br, CN, NO2, ═O, CO2H, —(CH2)nORf, S(O)pRf, C(═O)NRfRf, NRfC(═O)Rf, S(O)pNRfRf, NRfS(O)pRf, NRfC(═O)ORf, OC(═O)NRfRf and —(CH2)nNRfRf;
Rf, at each occurrence, is independently selected from H, C1-5alkyl (optionally substituted with halogen and OH), C3-6 cycloalkyl, and phenyl, or Rf and Rf together with the nitrogen atom to which they are both attached form a heterocyclic ring optionally substituted with C1-4alkyl;
n is independently selected from zero, 1, 2, and 3; and
p, at each occurrence, is independently selected from zero, 1, and 2.

### Claim 2 (depends on 1)

The compound according to claim 1, or a stereoisomer, an enantiomer, a diastereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein ring A is independently selected from
ring B is independently selected from
and 6-membered heteroaryl, each substituted with 1-4 R1;
R1 is independently selected from H, F, Cl, Br, NO2, —(CH2)nORb, (CH2)nS(O)pRc, —(CH2)nC(═O)Rb, —(CH2)nNRaRa, —(CH2)nC(═O)NRaRa, —(CH2)nNRaC(═O)Rb, C1-4 alkyl substituted with 0-3 Re and C3-6 cycloalkyl substituted with 0-3 Re;
R2 is independently selected from C2-5 alkyl substituted with 0-3 Re; C2-5 alkenyl, aryl substituted with 1-3 Re, heterocyclyl substituted with 0-3 Re, and C3-6 cycloalkyl; provided when R2 is C1-5 alkyl, the carbon atom and the groups attached thereto except the one attached to the pyrimidine ring may be replaced by O, N, and S;
R3 is independently selected from H, halogen, —(CH2)nORb, (CH2)nS(O)pRc, —(CH2)nC(═O)Rb, —(CH2)nNRaRa, —(CH2)nCN, —(CH2)nC(═O)NRaRa, —(CH2)nNHC(═O)Rb, —(CH2)nNHC(═O)NRaRa, —(CH2)nNHC(═O)ORb, —(CH2)nOC(═O)NRaRa, —(CH2)nC(═O)ORb, —(CH2)nS(O)pNRaRa, —(CH2)nNHS(O)pNRaRa, —(CH2)nNHS(O)pRc, C1-5 alkyl substituted with 0-3 Re, (CH2)n—C3-6 carbocyclyl substituted with 0-3 Re, and —(CH2)n-heterocyclyl comprising carbon atoms and 1-4 heteroatoms selected from N, NR3a, O, S, and substituted with 0-3 Re;
R3a is independently selected from H, C1-4 alkyl, —(CH2)n-aryl substituted with 0-3 Re, and —(CH2)n-heterocyclyl substituted with 0-3 Re;
Ra, at each occurrence, is independently selected from H, C1-6 alkyl substituted with 0-5 Re, —(CH2)n—C3-10carbocyclyl substituted with 0-5 Re, and —(CH2)n-heterocyclyl substituted with 0-5 Re; or Ra and Ra together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 Re;
Rb, at each occurrence, is independently selected from H, C1-6 alkyl substituted with 0-5 Re, C2-6 alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re, —(CH2)n—C3-10carbocyclyl substituted with 0-5 Re, and —(CH2)n-heterocyclyl substituted with 0-5 Re;
Re, at each occurrence, is independently selected from C1-6 alkyl (optionally substituted with halogen, OH, and CN), C2-6 alkenyl, C2-6 alkynyl, —(CH2)n—C3-6 cycloalkyl, —(CH2)n—C4-6 heterocyclyl, —(CH2)n-aryl, —(CH2)n-heteroaryl, F, Cl, Br, CN, NO2, ═O, CO2H, —(CH2)nORf, S(O)pRf, C(═O)NRfRf, NRfC(═O)Rf, S(O)pNRfRf, NRfS(O)pRf, NRfC(═O)ORf, OC(═O)NRfRf and —(CH2)nNRfRf;
Rf, at each occurrence, is independently selected from H, C1-5alkyl (optionally substituted with halogen and OH), C3-6 cycloalkyl, and phenyl;
n is independently selected from zero, 1, 2, and 3; and
p, at each occurrence, is independently selected from zero, 1, and 2.

### Claim 3 (depends on 2)

The compound according to claim 2 having Formula (II):
or a stereoisomer, an enantiomer, a diastereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:
ring A is independently selected from
R1 is independently selected from F, Cl, OH, C1-3 alkyl, and OC1-3 alkyl;
R1a is independently selected from F, Cl, and C1-2 alkyl;
R2 is independently selected from C2-5 alkyl substituted with 0-3 Re; C2-5 alkenyl, aryl substituted with 1-3 Re, heteroaryl substituted with 0-3 Re, C3-6 cycloalkyl and —(CH2)1-4OC1-5alkyl, and —(CH2)1-3OC3-6cycloalkyl;
R3 is independently selected from H, F, Cl, Br, —ORb, —(CH2)nC(═O)Rb, (CH2)nS(O)pRc, —(CH2)nC(═O)ORb, —(CH2)nNRaRa, CN, —(CH2)nC(═O)NRaRa, —(CH2)nNHC(═O)Rb, C1-4 alkyl substituted with 0-3 Re, (CH2)n—C3-6 carbocyclyl substituted with 0-3 Re, and —(CH2)n-heterocyclyl comprising carbon atoms and 1-4 heteroatoms selected from N, NR3aO, S, and substituted with 0-3 Re;
R3a is independently selected from H, CH3, —(CH2)n-aryl substituted with 0-3 Re, and —(CH2)n-heterocyclyl substituted with 0-3 Re;
Ra, at each occurrence, is independently selected from H, C1-6 alkyl substituted with 0-5 Re, —(CH2)n—C3-10carbocyclyl substituted with 0-5 Re, and —(CH2)n-heterocyclyl substituted with 0-5 Re; or Ra and Ra together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 Re;
Rb, at each occurrence, is independently selected from H, C1-6 alkyl substituted with 0-5 Re, C2-6 alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re, —(CH2)n—C3-10carbocyclyl substituted with 0-5 Re, and —(CH2)n-heterocyclyl substituted with 0-5 Re;
Re, at each occurrence, is independently selected from C1-6 alkyl (optionally substituted with F and Cl), OH, OCH3, OCF3, —(CH2)n—C3-6 cycloalkyl, —(CH2)n—C4-6 heterocyclyl, —(CH2)n-aryl, —(CH2)n-heteroaryl, F, Cl, Br, CN, NO2, ═O, and CO2H; and
n is independently selected from zero, 1, 2, and 3.

### Claim 4 (depends on 3)

The compound according to claim 3 having Formula (III):
or a stereoisomer, an enantiomer, a diastereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:
R1 is independently selected from C1-3 alkyl and —OC1-3 alkyl;
R2 is independently selected from C2-5 alkyl substituted with 0-3 Re; C2-5 alkenyl, aryl substituted with 1-3 Re, heteroaryl substituted with 0-3 Re, C3-6 cycloalkyl, —(CH2)1-4OC1-5alkyl, and —(CH2)1-3OC3-6cycloalkyl;
R3 is independently selected from H, F, Cl, Br, —OC1-4alkyl, S(O)2C1-4alkyl Re, —(CH2)nC(═O)Rb, —(CH2)nC(═O)ORb, —(CH2)nNRaRa, —C(═O)NRaRa, —NHC(═O)Rb, C1-4 alkyl substituted with 0-3 Re, C3-6 carbocyclyl selected from
and heterocyclyl selected from
Ra, at each occurrence, is independently selected from H, C1-6 alkyl substituted with 0-5 Re, —(CH2)n—C3-10carbocyclyl substituted with 0-5 Re, and —(CH2)n-heterocyclyl substituted with 0-5 Re; or Ra and Ra together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 ReRe, at each occurrence, is independently selected from C1-6 alkyl (optionally substituted with F and Cl), OH, OCH3, OCF3, —(CH2)n—C3-6 cycloalkyl, —(CH2)n—C4-6 heterocyclyl, —(CH2)n-aryl, —(CH2)n-heteroaryl, F, Cl, Br, CN, NO2, ═O, CO2H, and CONH2; and
n is independently selected from zero, 1, 2, and 3.

### Claim 5 (depends on 4)

The compound according to claim 4 having Formula (IIIa):
or a stereoisomer, an enantiomer, a diastereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:
R1 is independently selected from C1-3 alkyl and —OC1-3 alkyl;
R2 is independently selected from C2-5 alkyl substituted with 0-3 Re, phenyl substituted with 1-3 Re, 5-membered heteroaryl substituted with 0-3 Re, C3-6 cycloalkyl, —(CH2)1-4OC1-5alkyl, and —(CH2)1-3OC3-6cycloalkyl;
R3b is independently selected from H, F, Cl, and Br;
R3c is independently selected from H, (CH2)nNRaRa,
Ra, at each occurrence, is independently selected from H, C1-6 alkyl substituted with 0-5 Re, —(CH2)n—C3-10carbocyclyl substituted with 0-5 Re, and —(CH2)n-heterocyclyl substituted with 0-5 Re; or Ra and Ra together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 Re;
Re, at each occurrence, is independently selected from C1-6 alkyl (optionally substituted with F and Cl), OH, OCH3, OCF3, —(CH2)n—C3-6 cycloalkyl, —(CH2)n—C4-6 heterocyclyl, —(CH2)n-aryl, —(CH2)n-heteroaryl, F, Cl, Br, CN, NO2, ═O, CO2H and CONH2; and
n is independently selected from zero, 1, 2, and 3.

### Claim 6 (depends on 5)

The compound according to claim 5 or a stereoisomer, an enantiomer, a diastereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:
R2 is independently selected from C2-5 alkyl substituted with 0-3 Re; C2-5 alkenyl, phenyl substituted with 1-3 Re, 5-membered heteroaryl substituted with 0-3 Re, C3-6 cycloalkyl and CH2O(CH2)1-3CH3;
R3 is independently selected from H and —(CH2)0-1NRaRa;
Ra and Ra together with the nitrogen atom to which they are both attached form a heterocyclic ring selected from
Re, at each occurrence, is independently selected from C1-6 alkyl (optionally substituted with F and Cl), OH, OCH3, OCF3, —(CH2)n—C3-6 cycloalkyl, —(CH2)n—C4-6 heterocyclyl, —(CH2)n-aryl, —(CH2)n-heteroaryl, F, Cl, Br, CN, NO2, ═O, CO2H, and CONH2.

### Claim 7 (depends on 3)

A compound according to claim 3, or a stereoisomer, an enantiomer, a diastereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:
ring A is independently selected from
R1 is independently selected from F, Cl, OH, and OC1-4 alkyl;
R1a is independently selected from F, Cl, and C1-2 alkyl;
R2 is independently selected from C2-5 alkyl substituted with 0-3 Re; C2-5 alkenyl, phenyl substituted with 1-3 Re, 5- or 6-membered heteroaryl substituted with 0-3 Re, C3-6 cycloalkyl, and CH2O(CH2)1-3CH3;
R3 is independently selected from H, C1-4 alkyl substituted with 0-3 Re, and phenyl substituted with 0-3 Re;
R3a is independently selected from H, CH3, and —(CH2)n-phenyl substituted with 0-3 Re; and
Re, at each occurrence, is independently selected from C1-6 alkyl (optionally substituted with F and Cl), OH, OCH3, OCF3, —(CH2)n—C3-6 cycloalkyl, —(CH2)n—C4-6 heterocyclyl, —(CH2)n-aryl, —(CH2)n-heteroaryl, F, Cl, Br, CN, NO2, ═O, and CO2H.

### Claim 8 (depends on 1)

The compound according to claim 1 having Formula (IV):
or a stereoisomer, an enantiomer, a diastereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:
ring A is independently selected from
ring B is independently selected from
R1 is independently selected from H, F, Cl, Br, OC1-4 alkyl, CN, and C1-4 alkyl;
R2 is independently selected from C2-5 alkyl substituted with 0-3 Re; C2-5 alkenyl, phenyl substituted with 1-3 Re, 5- or 6-membered heteroaryl substituted with 0-3 Re, C3-6 cycloalkyl and CH2O(CH2)1-3CH3;
R3 is independently selected from H, F, Cl, Br, —ORb, —(CH2)nC(═O)Rb, (CH2)nS(O)pRc, —(CH2)nC(═O)ORb, —(CH2)nNRaRa, CN, —(CH2)nC(═O)NRaRa, —(CH2)nNHC(═O)Rb, C1-4 alkyl substituted with 0-3 Re, (CH2)n—C3-6 carbocyclyl substituted with 0-3 Re, and —(CH2)n-heterocyclyl substituted with 0-3 Re;
R3a is independently selected from H, CH3, —(CH2)n-aryl substituted with 0-3 Re, and —(CH2)n-heterocyclyl substituted with 0-3 Re;
R4 is independently selected from CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, and CH2OCH3;
Ra, at each occurrence, is independently selected from H, C1-6 alkyl substituted with 0-5 Re, —(CH2)n—C3-10carbocyclyl substituted with 0-5 Re, and —(CH2)n-heterocyclyl substituted with 0-5 Re; or Ra and Ra together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 Re;
Rb, at each occurrence, is independently selected from H, C1-6 alkyl substituted with 0-5 Re, C2-6 alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re, —(CH2)n—C3-10carbocyclyl substituted with 0-5 Re, and —(CH2)n-heterocyclyl substituted with 0-5 Re;
Re, at each occurrence, is independently selected from C1-6 alkyl (optionally substituted with F and Cl), OH, OCH3, OCF3, —(CH2)n—C3-6 cycloalkyl, —(CH2)n—C4-6 heterocyclyl, —(CH2)n-aryl, —(CH2)n-heteroaryl, F, Cl, Br, CN, NO2, ═O, CO2H, and CONH2; and
n is independently selected from zero, 1, 2, and 3.

### Claim 9 (depends on 8)

The compound according to claim 8 having Formula (V):
or a stereoisomer, an enantiomer, a diastereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:
R1 is independently selected from H, F, Cl, Br, OC1-4 alkyl, CN, and C1-4 alkyl;
R2 is independently selected from —CH2(CH2)1-3CH3, —CH2OCH(CH3)2, —(CH2)1-3C3-6cycloalkyl,
5-membered heteroaryl selected from
and CH2O(CH2)1-3CH3;
R3 is independently selected from H, F, Cl, Br, C3-6 cycloalkyl, phenyl substituted with 0-3 Re, and 5- or 6-membered heteroaryl substituted with 0-3 Re;
R4 is independently selected from CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, and CH2OCH3;
Re, at each occurrence, is independently selected from C1-6 alkyl (optionally substituted with F and Cl), OH, OCH3, OCF3, —(CH2)n—C3-6 cycloalkyl, —(CH2)n—C4-6 heterocyclyl, —(CH2)n-aryl, —(CH2)n-heteroaryl, F, Cl, Br, CN, NO2, ═O, CO2H, and CONH2; and
n is independently selected from zero, 1, 2, and 3.

### Claim 10 (depends on 9)

The compound according to claim 9 having Formula (VI):
or a stereoisomer, an enantiomer, a diastereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:
R1 is independently selected from H, F, Cl, Br, OC1-4 alkyl, CN, and C1-4 alkyl;
R3b is independently selected from H and F;
R3c is independently selected from
R4 is independently selected from CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, and CH2OCH3;
Re, at each occurrence, is independently selected from C1-6 alkyl (optionally substituted with F and Cl), OH, OCH3, OCF3, —(CH2)n—C3-6 cycloalkyl, —(CH2)n—C4-6 heterocyclyl, —(CH2)n-aryl, —(CH2)n-heteroaryl, F, Cl, Br, CN, NO2, ═O, CO2H, and CONH2; and
n is independently selected from zero, 1, 2, and 3.

### Claim 11 (depends on 1)

A compound according claim 1, wherein the compound is selected from the exemplified examples or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 1)

A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a compound of claim 1, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 12)

A method of treating cardiovascular diseases, comprising administering to a patient in need there of a therapeutically effective amount of the pharmaceutical composition of claim 12.

### Claim 14 (depends on 13)

The method of claim 13 wherein said cardiovascular diseases are coronary heart disease, stroke, heart failure, systolic heart failure, diastolic heart failure, diabetic heart failure, heart failure with preserved ejection fraction, cardiomyopathy, myocardial infarction, left ventricular dysfunction, left ventricular dysfunction after myocardial infarction, cardiac hypertrophy, myocardial remodeling, myocardial remodeling after infarction or after cardiac surgery and valvular heart diseases.
